Targeting FMRP: A new window for cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Fragile X mental retardation protein (FMRP) is regulated by Myc and overexpressed in various human and mouse tumors.
• FMRP plays a role in establishing an immunosuppressive tumor microenvironment by recruiting regulatory T cells (Tregs) and M2 macrophages via IL3, PROS1, and exosomes.

Purpose of the Study:

• To investigate the role of FMRP in regulating the tumor microenvironment and anti-tumor immunity.
• To explore the potential of FMRP knockout (FMRP-KO) as a strategy to enhance anti-tumor immune responses.

Main Methods:

• Analysis of FMRP expression in tumor tissues.
• Investigating the effects of FMRP knockout on immune cell recruitment and cytokine/chemokine secretion.
• Utilizing techniques to assess the interaction of FMRP with Tregs, M2 macrophages, and its influence on CD8+ T cell activation and recruitment.

Main Results:

• FMRP knockout (FMRP-KO) leads to increased secretion of CCL7 by tumor cells, directly activating and recruiting CD8+ T cells.
• FMRP-KO promotes M1 macrophage polarization, which in turn secretes CCL5, CXCL9, and CXCL10, indirectly recruiting CCR5 and CXCR4 receptor-positive CD8+ T cells.
• These findings suggest FMRP knockout enhances anti-tumor immunity by modulating both direct and indirect recruitment of cytotoxic CD8+ T cells.

Conclusions:

• FMRP actively suppresses anti-tumor immunity by fostering an immunosuppressive tumor microenvironment.
• FMRP knockout demonstrates a promising strategy to reprogram the tumor microenvironment towards an immune-permissive state, enhancing CD8+ T cell-mediated anti-tumor responses.
• Targeting FMRP could represent a novel therapeutic avenue for cancer treatment.